Claims for Patent: 9,101,615

Summary for Patent: 9,101,615

Title:	Intravenous formulations of neurokinin-1 antagonists
Abstract:	Pharmaceutical compositions for intravenous administration comprising the compound of Formula I ##STR00001## or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.
Inventor(s):	Wan; Jiansheng (Warren, NJ), Gupta; Pranav (Short Hills, NJ), Monteith; David (Pittstown, NJ), Bhattacharya; Soumendu (East Windsor, NJ)
Assignee:	OPKO Health, Inc. (Miami, FL)
Application Number:	12/855,889
Patent Claims:	1. A method for treating nausea and/or emesis in a patient in need of treatment, the method comprising intravenously administering to the patient an effective amount of a pharmaceutical composition comprising: a) a compound of Formula I ##STR00030## or a pharmaceutically acceptable salt thereof; b) macrogol 15-hydroxystearate in an amount of from about 0.50% to about 10.0% by weight of the total composition; c) a medium chain triglyceride in an amount of from about 0.10% to about 2.5% by weight of the total composition; d) a long chain triglyceride in an amount of from about 0.10% to about 1.5% by weight of the total composition; and e) at least one buffer, wherein the weight ratio of macrogol 15-hydroxystearate:medium chain triglyceride:long chain triglyceride in the composition is about 5-100:1-5:1, and wherein the pH of the composition is from about 6.5 to about 8.0; and with incidence of hemolysis that is below 20% when administered across a population. 2. The method of claim 1, wherein said pharmaceutical composition comprises: (a) a compound of Formula I ##STR00031## or a pharmaceutically acceptable salt thereof; (b) macrogol 15-hydroxystearate in an amount of about 4.4% by weight of the total composition; (c) at least one medium chain triglyceride in an amount of about 1.1% by weight of the total composition; (d) refined soybean oil in an amount of about 0.66% by weight of the total composition; and (e) a phosphate buffer, wherein the pH of the composition is about 7.5. 3. The method of claim 1, wherein said pharmaceutical composition comprises: (a) a compound of Formula I ##STR00032## or a pharmaceutically acceptable salt thereof; (b) macrogol 15-hydroxystearate in an amount of about 0.88% by weight of the total composition; (c) at least one medium chain triglyceride in an amount of about 0.22% by weight of the total composition; (d) refined soybean oil in an amount of about 0.12% by weight of the total composition; and (e) a phosphate buffer, wherein the pH of the composition is about 7.5. 4. The method of claim 1, wherein the medium chain triglyceride is selected from the group consisting of caprylic acid triglyceride, capric acid triglyceride, caprylic/capric acid triglyceride, trigylceride from coconut oil, caprylic/caprylic/lauric triglyceride, caprylic/caprylic/linoleic triglyceride, caprylic/caprylic/stearic triglyceride and combinations of two or more thereof. 5. The method of claim 1, wherein the long chain triglyceride is selected from the group consisting of soybean oil, corn oil, cottonseed oil, olive oil, peanut oil, safflower oil, sesame oil, shark liver oil, ethyl oleate, castor oil, monounsaturated omega-9 fatty acid and combinations of two or more thereof. 6. The method of claim 1, wherein the macrogol 15-hydroxystearate is present in an amount of from about 0.5% to about 10.0% by weight of the total composition; the medium chain triglyceride is present in an amount of from about 0.15% to about 1.5% by weight of the total composition; and the long chain triglyceride is present in an amount of from about 0.10% to about 1.2% by weight of the total composition. 7. The method of claim 1, wherein the macrogol 15-hydroxystearate is present in an amount of from about 0.88% to about 4.84% by weight of the total composition; the medium chain triglyceride is present in an amount of from about 0.20% to about 1.20% by weight of the total composition; and the long chain triglyceride is present in an amount of from about 0.10% to about 0.75% by weight of the total composition. 8. The method of claim 1, wherein the medium chain glyceride is caprylic/capric acid triglyceride and the long chain triglyceride is refined soybean oil. 9. The method of claim 1, wherein the pharmaceutically acceptable salt is a hydrochloride salt. 10. The method of claim 1, wherein the pH of the composition is from about 7 to about 8. 11. The method of claim 10, wherein the pH of the composition is about 7.5. 12. The method of claim 1, wherein the composition further comprises a tonicity adjuster and/or a pH adjuster. 13. The method of claim 1, wherein the at least one buffer is a phosphate buffer. 14. The method of claim 13, wherein the phosphate buffer is sodium phosphate buffer. 15. The method of any of claims 1, 2, and 3, wherein the pharmaceutical composition is administered by infusion. 16. The method of any of claims 1, 2, and 3, wherein the nausea and/or vomiting are induced by chemotherapy or are post-operative nausea and/or vomiting. 17. The method of any one of claim 1, 2 or 3, wherein the compound of Formula I, or the pharmaceutically acceptable salt thereof, is present in a concentration of from 1 mg/ml to 15 mg/ml. 18. The method of claim 17, wherein the compound of Formula I, or the pharmaceutically acceptable salt thereof, is present in a concentration of from 2 mg/ml to 10 mg/ml. 19. The method of claim 18, wherein the compound of formula I or the pharmaceutically acceptable salt thereof, is present in a concentration of 2 mg/ml. 20. The method of any of claims 1, 2, and 3, wherein the pharmaceutical composition comprises the crystalline monohydrate hydrochloride salt of the compound of Formula I. 21. A method of treating acute and/or delayed nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy comprising administration of an intravenous formulation comprising: a) a compound of Formula I ##STR00033## or a pharmaceutically acceptable salt thereof; b) macrogol 15-hydroxystearate in an amount of from about 0.50% to about 10.0% by weight of the total composition; c) a medium chain triglyceride in an amount of from about 0.10% to about 2.5% by weight of the total composition; d) a long chain triglyceride in an amount of from about 0.10% to about 1.5% by weight of the total composition; and e) at least one buffer, wherein the weight ratio of macrogol 15-hydroxystearate:medium chain triglyceride:long chain triglyceride in the composition is about 5-100:1-5:1, and wherein the pH of the composition is from about 6.5 to about 8.0; and with incidence of hemolysis that is below 20% when administered across a population. 22. The method of any of claims 1, 2, 3, and 21, wherein the patient is a primate or a companion animal. 23. The method of claim 22, wherein the primate is a human. 24. The method of any of claims 1, 2, 3, and 21, wherein the total daily dose of the compound of Formula I or pharmaceutically acceptable salt thereof is from 1 mg/kg to 9 mg/kg patient body weight. 25. The method of claim 1 or 21 wherein the medium chain glyceride is caprylic/capric acid triglyceride. 26. The method of claim 21, wherein said intravenous formulation comprises: (a) a compound of Formula I ##STR00034## or a pharmaceutically acceptable salt thereof; (b) macrogol 15-hydroxystearate in an amount of about 4.4% by weight of the total composition; (c) at least one medium chain triglyceride in an amount of about 1.1% by weight of the total composition; (d) refined soybean oil in an amount of about 0.66% by weight of the total composition; and (e) a phosphate buffer, wherein the pH of the composition is about 7.5. 27. The method of claim 21, wherein said intravenous formulation comprises: (a) a compound of Formula I ##STR00035## or a pharmaceutically acceptable salt thereof; (b) macrogol 15-hydroxystearate in an amount of about 0.88% by weight of the total composition; (c) at least one medium chain triglyceride in an amount of about 0.22% by weight of the total composition; (d) refined soybean oil in an amount of about 0.12% by weight of the total composition; and (e) a phosphate buffer, wherein the pH of the composition is about 7.5. 28. The method of claim 21, wherein the medium chain triglyceride is selected from the group consisting of caprylic acid triglyceride, capric acid triglyceride, caprylic/capric acid triglyceride, trigylceride from coconut oil, caprylic/caprylic/lauric triglyceride, caprylic/caprylic/linoleic triglyceride, caprylic/caprylic/stearic triglyceride and combinations of two or more thereof. 29. The method of claim 21, wherein the long chain triglyceride is selected from the group consisting of soybean oil, corn oil, cottonseed oil, olive oil, peanut oil, safflower oil, sesame oil, shark liver oil, ethyl oleate, castor oil, monounsaturated omega-9 fatty acid and combinations of two or more thereof. 30. The method of claim 21, wherein the macrogol 15-hydroxystearate is present in an amount of from about 0.5% to about 10.0% by weight of the total composition; the medium chain triglyceride is present in an amount of from about 0.15% to about 1.5% by weight of the total composition; and the long chain triglyceride is present in an amount of from about 0.10% to about 1.2% by weight of the total composition. 31. The method of claim 21, wherein the macrogol 15-hydroxystearate is present in an amount of from about 0.88% to about 4.84% by weight of the total composition; the medium chain triglyceride is present in an amount of from about 0.20% to about 1.20% by weight of the total composition; and the long chain triglyceride is present in an amount of from about 0.10% to about 0.75% by weight of the total composition. 32. The method of claim 21, wherein the medium chain glyceride is caprylic/capric acid triglyceride and the long chain triglyceride is refined soybean oil. 33. The method of claim 21, wherein the pharmaceutically acceptable salt is a hydrochloride salt. 34. The method of claim 21, wherein the compound of Formula I, or the pharmaceutically acceptable salt thereof, is present in a concentration of from 1 mg/ml to 15 mg/ml. 35. The method of claim 32, wherein the compound of Formula I, or the pharmaceutically acceptable salt thereof, is present in a concentration of from 2 mg/ml to 10 mg/ml. 36. The method of claim 33, wherein the compound of Formula I is present in a concentration of 2 mg/ml. 37. The method of claim 21, wherein the pH of the composition is from about 7 to about 8. 38. The method of claim 35, wherein the pH of the composition is about 7.5. 39. The method of claim 21, wherein the composition further comprises a tonicity adjuster and/or a pH adjuster. 40. The method of claim 21, wherein the at least one buffer is a phosphate buffer. 41. The method of claim 38, wherein the phosphate buffer is sodium phosphate buffer. 42. The method of claim 21, wherein the pharmaceutical composition is administered by infusion. 43. The method of any of claims 21, 26, and 27, wherein the intravenous formulation comprises the crystalline monohydrate hydrochloride salt of the compound of Formula I. 44. The method of any of claims 1, 2, 3, 21, 26, and 27 further comprising administration of at least one additional antiemetic agent.